Design Therapeutics (DSGN) director awarded 30,000 options at $10.55 strike

Rhea-AI Filing Summary

Design Therapeutics, Inc. director Rodney W. Lappe received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036.

According to the disclosure, these options were awarded as compensation and will vest in equal monthly installments over 12 months following June 9, 2026, and will in any case be fully vested by the company’s next annual stockholder meeting. Following this grant, Lappe holds derivative securities representing 30,000 underlying shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider LAPPE RODNEY W

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 30,000 options Exercise price: $10.55 per share Expiration date: June 8, 2036 +3 more

6 metrics

Option grant size 30,000 options Stock Option (right to buy) granted to director

Exercise price $10.55 per share Exercise price of stock options

Expiration date June 8, 2036 Option expiration date

Vesting schedule 12 equal monthly installments Over 12 months following June 9, 2026

Underlying shares 30,000 shares Common stock underlying the options

Post-grant derivative holdings 30,000 derivative securities Total derivative securities following transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, exercise price, Common Stock, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 10.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vest financial

"The shares subject to the option vest in equal monthly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LAPPE RODNEY W

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CALIFORNIA 92011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.55	06/09/2026		A		30,000		(1)	06/08/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

	/s/ Mustapha Parekh, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did DSGN director Rodney W. Lappe receive in this Form 4 filing?

Rodney W. Lappe received a grant of stock options for 30,000 shares of Design Therapeutics common stock. These options are a compensation award and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of the new DSGN stock options?

The new stock options for DSGN have an exercise price of $10.55 per share. This means Lappe can buy Design Therapeutics common stock at $10.55 regardless of the market price once the options vest.

How do the 30,000 DSGN options granted to Rodney Lappe vest?

The 30,000 options vest in equal monthly installments over 12 months following June 9, 2026. The filing also states the options will be fully vested by the date of Design Therapeutics’ next annual meeting of stockholders.

When do Rodney Lappe’s newly granted DSGN options expire?

The options granted to Rodney Lappe expire on June 8, 2036. After that expiration date, any unexercised options will no longer be usable to purchase Design Therapeutics common stock.

How many DSGN derivative securities does Rodney Lappe hold after this grant?

After this grant, Lappe holds derivative securities representing 30,000 underlying shares of Design Therapeutics common stock directly. This figure reflects the options reported in this Form 4 filing.